Apyx Medical Corporation (APYX)
NASDAQ:APYX
Want to see APYX full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.09Last Year’s EPS
-0.09Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed substantial positive operational and financial momentum driven by the AYON commercial launch and strong Surgical Aesthetics demand: double-digit revenue growth, expanding gross margins, reduced operating losses, improved adjusted EBITDA, a raised full-year revenue guide, and a healthy cash balance with a runway into 2027. Offsetting risks include a remaining GAAP net loss, tariff-related cost pressure, an expected long-term decline in the OEM business, some domestic generator sales decline/reclassification, and adoption timing dependency on the forthcoming power-liposuction label and international registrations. Overall, the positives—particularly the robust AYON ramp, international traction, margin expansion, and upgraded guidance—significantly outweigh the negatives.Company Guidance
Total Revenue Growth
Total Q1 2026 revenue increased 32% year-over-year to $12.5 million from $9.4 million in Q1 2025.
Surgical Aesthetics Segment Surge Driven by AYON
Surgical Aesthetics revenue rose 36% year-over-year to $10.7 million (from $7.9 million), driven by AYON body contouring system ramp in the U.S., increased single-use handpiece volume, and higher Renuvion generator sales internationally. This was the second full quarter of AYON sales following its commercial launch in Sept 2025.
Strong International Momentum
International revenue increased 63% year-over-year to $4.4 million while domestic revenue grew 20% to $8.1 million. Notable initial demand following regulatory approval in South Korea exceeded expectations.
Improved Profitability Metrics
Gross profit rose 40% year-over-year to $7.9 million and gross margin expanded to 63.5% from 60.1%, driven by favorable product/segment mix (higher Surgical Aesthetics contribution).
Operating Performance and Cash Flow Improvements
Loss from operations narrowed to $0.9 million (from $3.1 million). Net loss improved to $2.1 million or $(0.05) per share (from $4.2 million or $(0.10)). Adjusted EBITDA loss improved to $0.3 million (loss) from $2.4 million (loss). Cash used in operations was $0.6 million vs $0.7 million prior year; cash and equivalents totaled $31.1 million.
Upwardly Revised 2026 Guidance
Full-year 2026 revenue guidance raised to $59M–$60M (from $57.5M–$58.5M). Surgical Aesthetics revenue guidance increased to $54M–$55M (from $53M–$54M). OEM revenue guidance set at ~$5M (up from $4.5M guidance). Company expects full-year gross margins of ~62%–63% and operating expenses not to exceed $45M.
Product Roadmap and Regulatory Milestone
Company expects FDA 510(k) clearance for AYON to include power-assisted liposuction 'sometime this quarter,' which would expand AYON functionality to support multiple advanced fat removal modalities and is expected to broaden addressable market and adoption.
Disciplined Commercial Execution and Lean Cost Structure
Management highlighted a lean operating structure implemented ~a year ago that materially reduced operating expenses and cash burn, enabling selective reinvestment (e.g., AYON rollout). The commercial launch emphasized training and workflow integration to drive customer success.
APYX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
APYX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $2.92 | $3.56 | +21.92% |
Mar 10, 2026 | $3.43 | $3.45 | +0.58% |
Nov 06, 2025 | $3.14 | $3.35 | +6.69% |
Aug 07, 2025 | $1.96 | $2.18 | +11.22% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Apyx Medical Corporation (APYX) report earnings?
Apyx Medical Corporation (APYX) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is Apyx Medical Corporation (APYX) earnings time?
Apyx Medical Corporation (APYX) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is APYX EPS forecast?
APYX EPS forecast for the fiscal quarter 2026 (Q2) is -0.09.